Clario will become part of Thermo Fisher’s laboratory products and biopharma services segment.

Thermo Fisher Scientific has completed its acquisition of Clario Holdings for $8.875 billion in cash, plus potential ...

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the completion of its acquisition of Clario Holdings, Inc., a leading provider of endpoint data ...

Thermo Fisher plans to create a fast-growing business by integrating Clario’s data capture and management system with its ...

The Clario business will become part of Thermo Fisher’s laboratory products and biopharma services segment; In addition to ...

Scientific services company Thermo Fisher agreed to buy Clario in October for $8.88 billion in cash plus $125 million in January 2027, and then up to $400 million based on the bus ...

Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the Best Conservative Stocks to Buy Right Now. On March 24, the company ...

In today's ACT Brief, we examine Thermo Fisher's acquisition of Clario to expand clinical trial data infrastructure, how ...

Drug research is changing and there are opportunities for growth, says Christopher Fikry, the new CEO of clinical trial tech firm Clario. Fikry, who Clario named as its new chief last month, shared ...

Clinical trial tech company Clario has sealed its second acquisition in a week, doubling down further on neuroscience by picking up imaging specialist NeuroRx. NeuroRx founder and CEO Douglas Arnold, ...

Clario's third annual ESG report for the calendar year 2023 highlights advancements in responsible artificial intelligence (AI), employee program investments, and ambitious science-based ...